Premium
Safety and efficacy of microwave ablation for medically inoperable colorectal pulmonary metastases: Single‐centre experience
Author(s) -
Ferguson Craig D,
Luis Chris R,
Steinke Karin
Publication year - 2017
Publication title -
journal of medical imaging and radiation oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.31
H-Index - 43
eISSN - 1754-9485
pISSN - 1754-9477
DOI - 10.1111/1754-9485.12600
Subject(s) - medicine , microwave ablation , radiology , percutaneous , lung , adverse effect , response evaluation criteria in solid tumors , colorectal cancer , retrospective cohort study , surgery , progressive disease , chemotherapy , cancer
To evaluate the safety and therapeutic efficacy of percutaneous microwave ablation ( MWA ) for colorectal pulmonary metastases. Methods Retrospective review of CT ‐guided lung MWA at a single tertiary institution. Adverse events within 30 days of MWA were considered procedure‐related complications. Imaging follow‐up was with 18F‐fluorodeoxyglucose ( FDG ) positron emission tomography ( PET )/ CT and contrast‐enhanced CT . Response of index tumours was assessed using modified response evaluation criteria in solid tumours ( mRECIST ). Results The CT ‐guided lung MWA was performed in 14 patients with treatment of 20 colorectal pulmonary metastases during 19 procedures. Mean follow‐up from completion of the treatment protocol was 24.4 ± 11.8 months. Primary and secondary technique effectiveness rates were 75% and 50% respectively. Mean pre‐ and post‐procedural carcino‐embryonic antigen ( CEA ) levels were 7.9 ± 10.8 µg/L and 2.5 ± 2.1 µg/L respectively. Procedure‐related complications were major in three procedures (15.8%) and minor in six procedures (31.6%). No procedure‐related deaths occurred. Conclusion Microwave ablation is safe and efficacious in the local control of colorectal pulmonary metastases. The frequent systemic disease progression despite local control would favour a minimally invasive treatment option over invasive surgery in the setting of oligometastatic disease.